Co-Diagnostics, Inc. (Nasdaq: CODX) announced it has completed clinical and analytical performance studies for its PCR-based Flu A/B and RSV ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE